SRSF2 and acute myeloid leukemia: The presence of the RUNX1-RUNX1T1 fusion gene, or t(8;21)(q22;q22.1) translocation, is generally considered a favorable prognostic factor in AML [85]; however, a database analysis revealed that RUNX1 mutation, accounting for 10% of newly diagnosed AML, was independently associated with poor prognosis and co-mutations with epigenetic modifiers (e.g., additional sex combs-like 1 (ASXL1)) and/or spliceosome-related genes (e.g., serine/arginine-rich splicing factor 2 (SRSF2) and plant homeodomain-like finger (PHF6)) predicted notably worse outcomes [86].